Safety and Regulatory Status Both BPC-157 and TB-500 remain unapproved for human medical use and are not sanctioned by major drug regulatory agencies for therapeutic applications
Unlike many peptides used in research, BPC-157 has been described in the published literature as stable in human gastric juice without enzymatic degradation, and as effective in research models when administered without a delivery carrier
Besides c-Met inhibitors, many new therapeutic strategies have been developed, such as the use of miRNAs to regulate HGF/c-Met signaling pathways to inhibit liver cancer progression, targeting endocytosis and more downstream molecules, Hic-5 as a therapeutic strategy to reduce side effects of c-Met inhibitors, as well as herbal treatments
protect from light Single-dose devices (used once and discarded) have no "after first use" storage period because they should be discarded immediately after injection: Semaglutide (Wegovy) : Single-dose pen
The information above reflects general protocol guidelines your individual protocol may differ
